Kenneth Mills - Regenxbio CEO
| RGNX Stock | USD 16.83 0.19 1.14% |
CEO
Mr. Kenneth T. Mills is President, Chief Executive Officer, Executive Director of the company. He was our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FOXKISER, most recently as a Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the companys operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, a biotechnology company, where he served as Director of Business Development up through the companys acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. Mr. Mills qualifications to continue to serve as a member of the Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a seniorlevel executive in both early stage and mature biotechnology companies and his demonstrated business judgment. since 2009.
| Age | 49 |
| Tenure | 15 years |
| Address | 9804 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 240 552 8181 |
| Web | https://www.regenxbio.com |
Kenneth Mills Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kenneth Mills against Regenxbio stock is an integral part of due diligence when investing in Regenxbio. Kenneth Mills insider activity provides valuable insight into whether Regenxbio is net buyers or sellers over its current business cycle. Note, Regenxbio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Regenxbio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kenneth Mills over two weeks ago Disposition of 15000 shares by Kenneth Mills of Regenxbio at 3.76 subject to Rule 16b-3 |
Regenxbio Management Efficiency
The company has return on total asset (ROA) of (0.2349) % which means that it has lost $0.2349 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6365) %, meaning that it created substantial loss on money invested by shareholders. Regenxbio's management efficiency ratios could be used to measure how well Regenxbio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to rise to -0.57 in 2024. At this time, Regenxbio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 35 M in 2024, whereas Total Assets are likely to drop slightly above 487 M in 2024.Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 |
Regenxbio Leadership Team
Elected by the shareholders, the Regenxbio's board of directors comprises two types of representatives: Regenxbio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenxbio. The board's role is to monitor Regenxbio's management team and ensure that shareholders' interests are well served. Regenxbio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenxbio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Mills, CEO and President Director and Member of Disclosure Committee | ||
| Ram PharmD, Executive Operations | ||
| JD II, Executive Officer | ||
| Vittal Vasista, CFO, Sr. VP of Corporate Devel., Treasurer and Member of Disclosure Committee | ||
| Tricia Truehart, VP Communications | ||
| Olivier Danos, Chief Scientific Officer | ||
| Shiva Fritsch, Chief Officer | ||
| Curran MS, Executive COO | ||
| Dr JD, Executive Property | ||
| Andrew Yost, VP Devel | ||
| Stephen MD, Executive Officer |
Regenxbio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regenxbio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.92) % | ||||
| Operating Margin | (2.71) % | ||||
| Current Valuation | 655.8 M | ||||
| Shares Outstanding | 49.04 M | ||||
| Shares Owned By Insiders | 7.17 % | ||||
| Shares Owned By Institutions | 81.80 % | ||||
| Number Of Shares Shorted | 4.07 M | ||||
| Price To Earning | 12.80 X |
Currently Active Assets on Macroaxis
When determining whether Regenxbio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regenxbio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regenxbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regenxbio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Regenxbio Stock analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Regenxbio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regenxbio. If investors know Regenxbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regenxbio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.02) | Revenue Per Share 2.063 | Quarterly Revenue Growth (0.29) | Return On Assets (0.23) | Return On Equity (0.64) |
The market value of Regenxbio is measured differently than its book value, which is the value of Regenxbio that is recorded on the company's balance sheet. Investors also form their own opinion of Regenxbio's value that differs from its market value or its book value, called intrinsic value, which is Regenxbio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regenxbio's market value can be influenced by many factors that don't directly affect Regenxbio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regenxbio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regenxbio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regenxbio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.